PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06083857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase 1
Recruiting
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06066424
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
Phase 3
Recruiting
- Conditions
- Bone Metastases
- Interventions
- Drug: Radiation Therapy
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT06065449
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
NeoAdjuvant Theranostic Lutetium Study: the Nautilus Trial
Phase 1
Recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06066437
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT06065462
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Myeloma
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT06066359
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06053658
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Phase 2
Terminated
- Conditions
- Head NeckSquamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT06046482
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06049134
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Phase 2
Recruiting
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06043323
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath